Literature DB >> 22740920

Presence of EGFR mutation in pathologically non-malignant specimens from computed tomography-guided lung needle biopsies.

Tsuyoshi Ueno1, Junichi Soh, Takao Hiraki, Hiroaki Asano, Koichi Ichimura, Kentaro Shibamoto, Hideo Gobara, Susumu Kanazawa, Shinichi Toyooka, Shinichiro Miyoshi.   

Abstract

Activating mutations of the epidermal growth factor receptor (EGFR) gene are characteristic of non-small cell lung cancer (NSCLC). EGFR mutations were previously detected in histologically normal lung tissue around NSCLC tumors. Computed tomography-guided lung needle biopsy (CTNB) is an accurate and useful technique for the diagnosis of lung tumors. However, pathologically non-malignant cases occasionally become apparent following lung tumor resection. In this study, we determined the EGFR mutational status of lung tumors diagnosed as non-malignant in CTNB specimens, but diagnosed as NSCLC following surgical resection. Between 2000 and 2008, 1,109 CTNBs were performed at Okayama University Hospital. Among them, 15 cases were initially diagnosed as non-malignant by CTNB, but diagnosed as NSCLC following surgical resection as a result of a high likelihood of malignancy by clinical findings. Twelve paired DNAs of CTNB and corresponding resected specimens were available to examine the EGFR mutational status using a mutant-enriched PCR assay. EGFR mutations were detected in one out of 12 CTNB specimens and three of the corresponding resected tumors. This case harbored the same EGFR mutation in the CTNB specimen and resected tumor, but not in the distant corresponding non-malignant lung tissue. Our results indicated that the detection of EGFR mutations may therefore aid the diagnosis of NSCLC in pathologically non-malignant CTNB specimens.

Entities:  

Year:  2011        PMID: 22740920      PMCID: PMC3362587          DOI: 10.3892/ol.2011.471

Source DB:  PubMed          Journal:  Oncol Lett        ISSN: 1792-1074            Impact factor:   2.967


  15 in total

1.  Epidermal growth factor receptor mutations in needle biopsy/aspiration samples predict response to gefitinib therapy and survival of patients with advanced nonsmall cell lung cancer.

Authors:  Jin-Yuan Shih; Chien-Hung Gow; Chong-Jen Yu; Chih-Hsin Yang; Yih-Leong Chang; Meng-Feng Tsai; Ya-Chieh Hsu; Kuan-Yu Chen; Wen-Pin Su; Pan-Chyr Yang
Journal:  Int J Cancer       Date:  2006-02-15       Impact factor: 7.396

2.  Detection of EGFR gene mutation in lung cancer by mutant-enriched polymerase chain reaction assay.

Authors:  Hiroaki Asano; Shinichi Toyooka; Masaki Tokumo; Kouichi Ichimura; Keisuke Aoe; Sachio Ito; Kazunori Tsukuda; Mamoru Ouchida; Motoi Aoe; Hideki Katayama; Akio Hiraki; Kazuro Sugi; Katsuyuki Kiura; Hiroshi Date; Nobuyoshi Shimizu
Journal:  Clin Cancer Res       Date:  2006-01-01       Impact factor: 12.531

Review 3.  Incidentally detected small pulmonary nodules on CT.

Authors:  A J Edey; D M Hansell
Journal:  Clin Radiol       Date:  2009-07-08       Impact factor: 2.350

4.  Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR.

Authors:  Makoto Maemondo; Akira Inoue; Kunihiko Kobayashi; Shunichi Sugawara; Satoshi Oizumi; Hiroshi Isobe; Akihiko Gemma; Masao Harada; Hirohisa Yoshizawa; Ichiro Kinoshita; Yuka Fujita; Shoji Okinaga; Haruto Hirano; Kozo Yoshimori; Toshiyuki Harada; Takashi Ogura; Masahiro Ando; Hitoshi Miyazawa; Tomoaki Tanaka; Yasuo Saijo; Koichi Hagiwara; Satoshi Morita; Toshihiro Nukiwa
Journal:  N Engl J Med       Date:  2010-06-24       Impact factor: 91.245

5.  EGFR tyrosine kinase domain mutations are detected in histologically normal respiratory epithelium in lung cancer patients.

Authors:  Ximing Tang; Hisayuki Shigematsu; B Nebiyou Bekele; Jack A Roth; John D Minna; Waun Ki Hong; Adi F Gazdar; Ignacio I Wistuba
Journal:  Cancer Res       Date:  2005-09-01       Impact factor: 12.701

6.  Usefulness of EGFR mutation screening in pleural fluid to predict the clinical outcome of gefitinib treated patients with lung cancer.

Authors:  Junichi Soh; Shinichi Toyooka; Keisuke Aoe; Hiroaki Asano; Syuji Ichihara; Hideki Katayama; Akio Hiraki; Katsuyuki Kiura; Motoi Aoe; Yoshifumi Sano; Kazuro Sugi; Nobuyoshi Shimizu; Hiroshi Date
Journal:  Int J Cancer       Date:  2006-11-15       Impact factor: 7.396

7.  The relationship between epidermal growth factor receptor mutations and clinicopathologic features in non-small cell lung cancers.

Authors:  Masaki Tokumo; Shinichi Toyooka; Katsuyuki Kiura; Hisayuki Shigematsu; Kunitoshi Tomii; Motoi Aoe; Kouichi Ichimura; Toshihide Tsuda; Masaaki Yano; Kazunori Tsukuda; Masahiro Tabata; Hiroshi Ueoka; Mitsune Tanimoto; Hiroshi Date; Adi F Gazdar; Nobuyoshi Shimizu
Journal:  Clin Cancer Res       Date:  2005-02-01       Impact factor: 12.531

8.  EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy.

Authors:  J Guillermo Paez; Pasi A Jänne; Jeffrey C Lee; Sean Tracy; Heidi Greulich; Stacey Gabriel; Paula Herman; Frederic J Kaye; Neal Lindeman; Titus J Boggon; Katsuhiko Naoki; Hidefumi Sasaki; Yoshitaka Fujii; Michael J Eck; William R Sellers; Bruce E Johnson; Matthew Meyerson
Journal:  Science       Date:  2004-04-29       Impact factor: 47.728

9.  CT-guided transthoracic fine needle aspiration of pulmonary lesions: accuracy and complications in 134 cases.

Authors:  Bahadir Taha Uskül; Hatice Türker; Mertol Gökçe; Aydin Kant; Sinan Arslan; Fatma Emre Turan
Journal:  Tuberk Toraks       Date:  2009

10.  CT fluoroscopy-guided biopsy of 1,000 pulmonary lesions performed with 20-gauge coaxial cutting needles: diagnostic yield and risk factors for diagnostic failure.

Authors:  Takao Hiraki; Hidefumi Mimura; Hideo Gobara; Toshihiro Iguchi; Hiroyasu Fujiwara; Jun Sakurai; Yusuke Matsui; Daisaku Inoue; Shinichi Toyooka; Yoshifumi Sano; Susumu Kanazawa
Journal:  Chest       Date:  2009-05-08       Impact factor: 9.410

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.